3 research outputs found
IGH::CD274 (PDâL1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
Abstract Diffuse large B cell lymphoma (DLBCL) expresses abundant programmed death ligand 1 (PDâL1), which shields tumor cells from immune attacks through the PDâL1/PDâ1 signaling axis. The mechanism of PDâL1 overexpression includes the deletion of the 3â˛end of PDâL1, which increases its mRNA stability, and the gain or amplification of PDâL1. Previous studies found two cases of DLBCL carrying an IGH::PDâL1 by whole genome sequencing. We describe two more such cases by a targeted DNA nextâgeneration sequencing (NGS) capable of detecting IGH rearrangements, leading to PDâL1 overexpression. DLBCL with PDâL1 overexpression is often resistant to RâCHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone). Our patients responded to a combination of RâCHOP and a PDâ1 inhibitor